OncoSil Medical has secured $5.6 million in fresh capital from its three biggest institutional shareholders, giving the Sydney-based medical device company the financial firepower to launch its targeted radiation therapy in the United States and Australia after years of regulatory work.
Pengana High Conviction Equities Fund, Regal Partners and Australian Ethical Investments have each committed to the raise, which combines a $4 million share placement priced at $1.00 with roughly $1.6 million from the early exercise of about 1.8 million listed options priced at $0.90.
The placement price sits at a 9.9 per cent premium to the company's last traded share price on 7 September 2026, a detail management is treating as a vote of confidence from its own largest backers rather than a discount grab typical of many capital raises. New shares from both the placement and the option exercise are expected to be allotted on 10 September 2026, with normal trading due to resume the following day.
The money arrives at what the company is calling a pivotal moment. OncoSil entered its 2027 financial year having cleared both of the regulatory hurdles it had been chasing. Australia's Therapeutic Goods Administration approved the device in May 2026 for use alongside gemcitabine-based chemotherapy in patients with locally advanced pancreatic cancer, while the United States Food and Drug Administration followed in August 2026, granting approval under its Humanitarian Device Exemption pathway for a rare bile duct cancer known as distal cholangiocarcinoma. With those approvals in hand, OncoSil's device is now cleared for sale in more than 30 countries.
Chairman Dr Thomas Duthy said the willingness of the company's major shareholders to both commit new capital and exercise options well ahead of their June 2027 expiry reflected confidence in the path ahead. He framed the raise as support for a company moving into commercial operation in two of its most important markets with what he described as a strengthened balance sheet.
Once the raise settles, OncoSil expects its pro forma cash position to reach $12.1 million, built on cash reserves of $6.5 million at the end of June 2026 plus the new funds. That buffer is meant to carry the company through a busy first half of its 2027 financial year, during which it is targeting completion of a study funded by Germany's Gemeinsamer Bundesausschuss, two additional regulatory filings in Europe and the start of manufacturing at its Sydney facility, run jointly with Cyclotek.
The device at the centre of all this activity, marketed as OncoSil, is a single-use brachytherapy implant that delivers a precise dose of beta radiation from Phosphorus-32 microparticles directly into a tumour, sparing surrounding healthy tissue in a way external beam radiotherapy cannot easily match. In the United States, it is approved specifically for unresectable, non-metastatic distal cholangiocarcinoma, a rare and often late-diagnosed bile duct cancer with a poor prognosis.
